MIV 160

Drug Profile

MIV 160

Alternative Names: MIV-160

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medivir AB
  • Developer Beijing Mefuvir Medicinal Technology
  • Class Antivirals
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended HIV infections
  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in China (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in China (Topical)
  • 21 Aug 2007 Medivir has transferred the licensing rights of MIV 160 from Guangdong Lantai Viewland Pharmaceutical to Beijing Mefuvir Medicinal Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top